An undated photo provided by the German pharmaceutical company BioNTech shows a vial of BNT162, the COVID-19 vaccine candidate developed with Pfizer. Who will get the vaccine, and how much of it, are decisions that still have to be sorted out if it wins authorization. (BioNTech via The New York Times) 